Skip to main content

Animations

MJFF Publications

4201 - 4210 of 8966 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2023
  • 2023
  • Summary Details
    OPEN
    Title: Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study
    Journal Name: Brain Sciences
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/brainsci12050661
    Citation Count: 11
  • Issue Overview
    2022
    Summary Details
    RESTRICTED
    Title: Issue Overview
    Journal Name: Continuum
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1212/01.con.0000892540.33029.c0
    Citation Count: 0
  • Issue Overview
    2022
    Summary Details
    RESTRICTED
    Title: Issue Overview
    Journal Name: Continuum
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1212/01.con.0000840008.09408.75
    Citation Count: 0
  • Editorial introductions
    2022
    Summary Details
    RESTRICTED
    Title: Editorial introductions
    Journal Name: Current Opinion in Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1097/wco.0000000000001027
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Cognitive-Driven Activities of Daily Living Impairment as a Predictor for Dementia in Parkinson Disease
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000201201
    Citation Count: 26
  • 2022 Emerging Science Abstracts
    2022
    Summary Details
    RESTRICTED
    Title: 2022 Emerging Science Abstracts
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000200917
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Lifestyle Interventions for the Prevention of Parkinson Disease
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000200787
    Citation Count: 52
  • Quality of Life for Patients With Parkinson Disease
    2022
    Summary Details
    RESTRICTED
    Title: Quality of Life for Patients With Parkinson Disease
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000200741
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Testing for Allele-specific Expression from Human Brain Samples
    Journal Name: BIO-PROTOCOL
    Publisher: Bio-Protocol, LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.21769/bioprotoc.4832
    Citation Count: 0
  • BKCa nitrosylation is associated with cerebral microvascular dysfunction in female 5x-FAD mice
    2023
    Summary Details
    RESTRICTED
    Title: BKCa nitrosylation is associated with cerebral microvascular dysfunction in female 5x-FAD mice
    Journal Name: Physiology
    Publisher: American Physiological Society
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1152/physiol.2023.38.s1.5731336
    Citation Count: 0
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.